key: cord-1015274-39u1luqn
authors: Brown, Jonathan C.; Goldhill, Daniel H.; Zhou, Jie; Peacock, Thomas P.; Frise, Rebecca; Goonawardane, Niluka; Baillon, Laury; Kugathasan, Ruthiran; Pinto, Andreia L.; McKay, Paul F.; Hassard, Jack; Moshe, Maya; Singanayagam, Aran; Burgoyne, Thomas; Barclay, Wendy S.
title: Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape
date: 2021-02-24
journal: bioRxiv
DOI: 10.1101/2021.02.24.432576
sha: 9df030e610e06a424680cf05ad0162269cc34f10
doc_id: 1015274
cord_uid: 39u1luqn

Lineage B.1.1.7 (Variant of Concern 202012/01) is a new SARS-CoV-2 variant which was first sequenced in the UK in September 2020 before becoming the majority strain in the UK and spreading worldwide. The rapid spread of the B.1.1.7 variant results from increased transmissibility but the virological characteristics which underpin this advantage over other circulating strains remain unknown. Here, we demonstrate that there is no difference in viral replication between B.1.1.7 and other contemporaneous SARS-CoV-2 strains in primary human airway epithelial (HAE) cells. However, B.1.1.7 replication is disadvantaged in Vero cells potentially due to increased furin-mediated cleavage of its spike protein as a result of a P681H mutation directly adjacent to the S1/S2 cleavage site. In addition, we show that B.1.1.7 does not escape neutralisation by convalescent or post-vaccination sera. Thus, increased transmission of B.1.1.7 is not caused by increased replication, as measured on HAE cells, or escape from serological immunity.

However, other than investigating its antigenicity, no studies have yet reported on the 109 virological characteristics of the B.1.1.7 variant which might contribute to its emergence and spread. 110

In this study, we experimentally characterised a panel of B.1.1.7 isolates. We tested whether B.1.1.7 111 shows enhanced replication compared to contemporaneous strains in Vero cells or in primary human 112 airway epithelial cells grown at air liquid interface. We investigated whether B. Figure 1A ). The mode area of plaques produced by the historic WT 127 SARS-CoV-2 isolate (IC19) collected from a patient in March 2020 and containing D614G, was ≥ 0.10 128 pixel 2 (x10 3 ), whereas the B.1.1.7 variants produced plaques of ≤ 0.06-0.08 pixel 2 (x10 3 ) ( Figure 1B, isolates and again virus released from infected cells was quantified by qPCR ( Figure 2A ). In Vero cells, 157 the B.1.1.7 isolate again displayed a significant growth defect. However, in HAE cells, the three isolates 158 showed no significant difference in growth kinetics. To further confirm the differential growth 159 phenotype of B.1.1.7 in different cell types was consistent, we infected Vero or HAE cells with a 160 different B.1.1.7 isolate alongside the B.1.258 strain ( Figure 2B ). Again, a significant defect was seen 161 for B.1.1.7 replication in Vero cells but there was no difference in replication kinetics in HAE cells. The potential escape of newly arising SARS-CoV-2 variants from neutralising antibodies raised 206 against previous strains is a global concern, particularly with vaccine efforts accelerating in many 207 regions. To test whether B.1.1.7 lineage escapes from neutralising antibodies, we carried out live virus 208 neutralisation assays to assess sera neutralisation of B.1.1.7 isolate 229 with WT IC19 as a comparator. SARS-CoV-2-specific antibodies to segregate HCW into individuals who were pre-exposed to virus 235 (n=5) and those who were naïve on the day of vaccination (n=5). The post-vaccination sera were then 236 assessed for neutralising antibodies against B.1.1.7 isolate 246 and IC19 ( Figure 4C ). Neutralising antibody titres post-vaccination were significantly higher in sera from pre-exposed (red lines) 238 compared to naive HCW (black lines) with median titres against IC19 of 2038 and 32 respectively. Post-239 vaccination sera from pre-exposed HCW also neutralised B.1.1.7 well with a median titre of 968 240 although 3/5 sera showed a greater than 2-fold decrease (2.1-fold to 3.0-fold) in their ability to 241 CoV-2 lineage B.1.1.7 virus by convalescent and post- to IC19. HCW sera were divided into those who had been exposed to SARS-CoV-2 prior to receiving the (Figures 1 and 2) . Our previous work highlighted that S1/S2 cleavage in the producer cell, 284 conferred by a polybasic stretch at the cleavage site, is advantageous in cells expressing abundant 285 TMPRSS2 but deleterious in cells lacking TMPRSS2 such as Vero cells (Peacock et al., 2020) . Analysis 286 here revealed that the P681H substitution directly adjacent to the S1/S2 cleavage site resulted in 287 increased cleavage of S ( Figure 3 ) and could be responsible for the reduced entry into Vero cells. 288 However, increased cleavage as an explanation for the deleterious effect in Vero cells was not 289 accompanied by a corresponding advantage in HAE cells. It is possible that increased cleavage could 290 be beneficial to transmission and entry into the human airway, but that this phenotype is not observed 291 when infecting HAE cultures with a relatively large amount of virus compared to the likely dose during 292 transmission. Further experiments to establish the lowest dose required to initiate infection in vitro 293 and in vivo may clarify this. Additionally, the decreased growth on Vero cells means that care must be 294 taken when growing B.1.1.7 viral stocks since deletion or mutation of the S1/S2 cleavage site might 295 be selected for in these cells. Viral stocks should be sequenced to confirm that the cleavage site 296 remains intact. In addition, viral titres calculated on Vero cells may lead to an underestimation of the 297 number of infectious viruses due to the high pfu:genome ratio. 298

We confirmed that B.1.1.7 does not escape from antibody immunity after natural infection 299 with previously circulating variants, or vaccine expressing the S protein of older variants, suggesting 300 that immune escape does not account for increased transmission (Figure 4 ). This is unsurprising given The cells were dissociated from the brush by gentle agitation before seeding into a single well of a 351 collagen (PureCol from Sigma Aldrich) coated plate. Once confluent the cells were passaged and 352 expanded further in a flask before passaging a second time and seeding onto transwell inserts (6.5 mm 353 diameter, 0.4 µm pore size, Corning) at a density of 24,000 cells per insert. Cells were cultured in 354

PneumaCult-Ex Plus (STEMCELL Technologies, Cambridge, UK) until confluent, at which point the 355 media was replaced with PneumaCult-ALI in the basal chamber and apical surface exposed to provide 356 an air liquid interface (ALI). Cilia were observed between 4-6 weeks post transition to ALI. 357

Sera were collected under ethical approval as stated in the Ethical Approval and heat-359 inactivated at 56°C for 30 minutes before use in assays. Virus inoculum were serially diluted in serum-free DMEM (1:10) supplemented with 1% NEAA 371 and 1% P/S, and added to Vero cell monolayers at 37°C for 1 h. Inoculum was then removed and plates 372 were overlaid with DMEM containing 0.2% w/v bovine serum albumin, 0.16% w/v NaHCO3, 10 mM 373 HEPES, 2mM L-Glutamine, 1x P/S, and 0.6% w/v agarose at 37°C for 3 d. The overlay was then 374 removed, and monolayers were stained with crystal violet solution. Plates were then washed with tap 375 water, dried and scanned on a flatbed office scanner at 600 dots per inch (dpi). Images were analysed 376 using the Analyze Particles module of Fiji (ImageJ). Areas of ≥ 300 plaques were measured for each 377 virus variant and expressed in pixels 2 . Virus plaque sizes were compared using the Kolmogorov-378

Smirnov test with Bonferroni correction (Prism 9.0; GraphPad). P ≤0.05 significant difference from WT. Pseudovirus assays 418 SARS-CoV-2 spike-bearing lentiviral pseudotypes (PV) were generated as previously described 419 (Peacock et al., 2020) . PV for western blot analysis were concentrated by ultracentrifugation at 420 100,000 x g for 2 hours over a 20% (w/v) sucrose cushion. PV neutralisation assays were performed 421 by serially diluting sera in 293T growth media and incubating for 1 h at 37 o C with equal concentrations 422 of PV. The PV/antisera mix was then added onto 293T-ACE2 cells. Serum dilutions were performed in 423 duplicate. 293T-ACE2 were transduced for 48 hours before lysis with reporter lysis buffer (Promega). 424

Luciferase luminescence was read on a FLUOstar Omega plate reader (BMF Labtech) using the 425 Luciferase Assay System (Promega). 426

Western blot analysis mercaptoethanol and run on SDS-PAGE gels. After semi-dry transfer onto nitrocellulose membrane, 429 membranes were probed with mouse anti-p24 (abcam; ab9071), rabbit anti-SARS spike protein 430 (NOVUS; NB100-56578) or rabbit anti-SARS-CoV-2 nucleocapsid (SinoBiological; 40143-R019). Near 431 infra-red (NIR) secondary antibodies, IRDye® 680RD Goat anti-mouse (abcam; ab216776) and IRDye® 432 800CW Goat anti-rabbit (abcam; ab216773) were subsequently used to probe membranes. Western 433 blots were visualised using an Odyssey Imaging System (LI-COR Biosciences). 1 -Replication kinetics of B.1.1.7 and non-B.1.1.7 

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent 472 plasma

Increased hazard of mortality in cases compatible with SARS-CoV-2 variant of 475 concern 202012/1 -a matched cohort study. Population Health Sciences

Persistence 478 and Evolution of SARS-CoV-2 in an Immunocompromised Host

SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of 488 Concern 202012/01

SARS-CoV-2 491 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal 492 antibodies Herbert Virgin

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary 495 findings

Early analysis of a potential link between viral load and the N501Y mutation in the 498 SARS-COV-2 spike protein

Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants 502 affecting amino acid position 677

A Multibasic Cleavage Site in the Spike 505 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-508 2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

SARS-CoV-2 evolution during treatment of chronic infection

Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion 521 ∆H69/V70

S-variant SARS-CoV-2 is associated with significantly higher viral loads in samples tested by 524

Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 1 528 variant relative to non-B.1.1.7 SARS-CoV-2 2 3 * denotes equal contribution

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. BioRxiv : 532 The Preprint Server for Biology

Natural deletions in the SARS-CoV-2 spike glycoprotein 536 drive antibody escape

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human 539 sera. Science, eabg6105

Tracking 541 the international spread of SARS-CoV-2 lineages B

The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for 544 transmission due to enhanced replication in airway cells

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by 548 a novel set of spike mutations

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice 551 and is neutralized by convalescent and post-vaccination human sera Contributed equally

SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to 555 control replication in lung epithelial cells

The impact of Spike 558 mutations on SARS-CoV-2 neutralization

Vaccine-induced immunity provides more robust 562 heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints 566 on Folding and ACE2 Binding

Journal Pre-proof Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and 570 vaccine sera

Emergence and rapid spread of a new severe acute respiratory 573 syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike

Evaluating 577 the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological 581 and genetic data

Increased infections, but not viral burden, with a new SARS-CoV-2 variant

Increased Resistance of 587 SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

593 (2021). mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global 594 SARS-CoV-2 variants

Evasion of Type I 597 Interferon by SARS-CoV-2

Neutralization of 600 SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

The ORF8 603 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I

A genome-wide CRISPR screen 606 identifies host factors that regulate SARS-CoV-2 entry